Dicerna Pharmaceuticals
Feb 5, 2014

Dicerna Announces Participation in Panel on RNAi Therapeutics at 16th Annual BIO CEO and Investor Conference on February 10th

WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced its participation in a panel discussion on RNAi therapeutics at the 16th Annual BIO CEO & Investor Conference. Douglas M. Fambrough, PhD, the company's President and CEO, is scheduled to take part in a Therapeutic Workshop entitled: "Delivering the [RNAi] Goods" to be held on Monday, February 10th, at 10:30 a.m. Eastern Standard Time.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

Dicerna Pharmaceuticals, Inc.
James E. Dentzer, 617-612-6204
Chief Financial Officer
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
Senior Vice President

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media